|
Market Closed -
Nasdaq
04:00:01 2026-09-30 pm EDT
|
5-day change | 1st Jan Change | ||
| 32.41 USD | +2.43% |
|
-3.28% | +19.33% |
| Sep. 22 | Top Midday Decliners | MT |
| Sep. 22 | Celldex Therapeutics, Inc. - Special Call |
| Market Cap | 2.48B 2.19B 2.07B 1.87B 3.53B 238B 3.58B 24.83B 9.56B 122B 9.33B 9.13B 391B | P/E 2026 * |
-7.54x | P/E 2027 * | -7.41x |
|---|---|---|---|---|---|
| Enterprise Value | 1.82B 1.61B 1.52B 1.37B 2.59B 175B 2.62B 18.21B 7.01B 89.28B 6.84B 6.69B 287B | EV / Sales 2026 * |
985x | EV / Sales 2027 * | 186x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CLDX | Delayed | |
CBOE
| CLDX | Real-time | |
|
Tradegate
| TCE2 | Real-time | |
|
Börse Stuttgart
| TCE2 | Delayed | |
|
Deutsche Boerse AG
| TCE2 | Delayed | |
|
Berne S.E.
| TCE1 | End-of-day quote | |
|
Boerse Muenchen
| TCE2 | Real-time |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | +2.43% | ||
| 1 week | -3.28% | ||
| Current month | -18.22% | ||
| 1 month | -17.15% | ||
| 3 months | -13.43% | ||
| 6 months | +6.96% | ||
| Current year | +19.33% |
| 1 week | 30.38 |  | 32.76 |
| 1 month | 30.38 | | 41.62 |
| Current year | 22.33 | | 45.14 |
| 1 year | 22.1 | | 45.14 |
| 3 years | 14.4 | | 53.18 |
| 5 years | 14.4 | | 57.2 |
| 10 years | 1.5 | | 75.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 2014-07-29 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 2008-08-31 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 2009-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 2008-11-30 |
Harry Penner
CHM | Chairman | 80 | 2025-06-04 |
Herbert Conrad
BRD | Director/Board Member | 93 | 2008-02-29 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/25/26 | Free | Chief Technology Officer | 57,000 | 0.0726% | ||
| 6/25/26 | Free | Executive/Senior Manager | 20,000 | 0.0255% | ||
| 6/25/26 | Free | Director | 26,000 | 0.0331% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.43% | -3.28% | +23.75% | +17.77% | 2.48B | |
| +4.16% | -0.30% | +58.96% | +94.17% | 71.53B | |
| -0.19% | -1.01% | +38.55% | +83.85% | 60.12B | |
| -1.51% | +2.20% | +10.66% | +35.15% | 48.85B | |
| -0.05% | -0.46% | +48.77% | +36.65% | 44.28B | |
| +0.38% | +6.43% | +345.54% | +641.55% | 43.83B | |
| +0.18% | -0.58% | +9.95% | +103.45% | 41.53B | |
| -0.67% | -0.45% | +4.47% | +46.37% | 30.13B | |
| +4.77% | +6.46% | +41.54% | +22.78% | 27.98B | |
| -1.29% | -5.53% | -19.42% | +352.04% | 25.25B | |
| Average | +0.82% | -0.13% | +56.28% | +143.38% | 39.6B | |
| Weighted average by Cap. | +0.81% | +0.59% | +64.74% | +147.73% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.85M 1.63M 1.54M 1.39M 2.63M 177M 2.66M 18.49M 7.12M 90.63M 6.95M 6.79M 291M | 9.95M 8.79M 8.31M 7.51M 14.16M 954M 14.33M 99.49M 38.31M 488M 37.38M 36.56M 1.57B |
| Net income | -319M -282M -266M -241M -454M -30.58B -460M -3.19B -1.23B -15.64B -1.2B -1.17B -50.22B | -361M -319M -301M -272M -514M -34.59B -520M -3.61B -1.39B -17.68B -1.36B -1.33B -56.79B |
| Net Debt | -662M -585M -553M -499M -942M -63.46B -954M -6.62B -2.55B -32.45B -2.49B -2.43B -104B | -633M -559M -529M -478M -901M -60.7B -912M -6.33B -2.44B -31.04B -2.38B -2.33B -99.66B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-30 | $32.41 | +2.43% | 1,993,708 |
| 26-09-29 | $31.64 | +0.48% | 2,029,557 |
| 26-09-28 | $31.49 | +1.25% | 1,824,249 |
| 26-09-25 | $31.10 | -1.21% | 2,023,927 |
| 26-09-24 | $31.48 | +1.16% | 2,297,688 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CLDX Stock
Select your edition
All financial news and data tailored to specific country editions
